<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081939</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2003-33</org_study_id>
    <nct_id>NCT00081939</nct_id>
  </id_info>
  <brief_title>UARK 2003-33, Total Therapy III</brief_title>
  <official_title>A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma
      Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total
      Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had
      better outcomes (meaning patients have lived longer and had better responses to treatment)
      when compared to patients treated with standard chemotherapy.

      With this new study, Total Therapy III, researchers will take what they have learned from the
      first two studies and add new treatment strategies to try to improve the outcomes even more,
      especially for patients with chromosome abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.1 To determine, in a historical comparison with TT II (Thalidomide arm), whether two cycles
      of VDTPACE induction (instead of four induction cycles in TT II) followed by more timely MEL
      200-based transplant with DEX + THAL between transplants can:

      1.1.1 Increase the CR frequency from 50% to 60% at 18 months from initiation of therapy;

      1.1.2 Increase &gt; n-CR rate pre-transplant #1 from 20% to 40%;

      1.1.3 Raise 2-year EFS rates from 55% to 75% in patients with CA and from 80% to 95%, in
      patients without CA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment</measure>
    <time_frame>3 years</time_frame>
    <description>In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a &gt;25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects &gt; 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Two cycles of induction on days 1,4,8,11 at 1.0mg/m^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m^2. Maintenance year one 1.0mg/m^2 1,4,8,11 q 28 days.</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Induction Inclusion Criteria:

          -  Patients must have newly diagnosed active MM requiring treatment. Patients with a
             previous history of smoldering myeloma will be eligible if there is evidence of
             progressive disease requiring chemotherapy.

          -  Protein criteria must be present (quantifiable M-component of IgG, IgA, IgD, or IgE
             and/or urinary kappa or lambda light chain or Bence Jones protein) in order to
             evaluate response. Non-secretory patients are eligible provided the patient has &gt; 20%
             plasmacytosis or multiple (&gt;3) focal plasmacytomas on MRI or diffuse hyperintense
             signal on STIR images in the absence of hematopoietic growth factors.

          -  Patients must have received no more than one cycle of prior chemotherapy for this
             disease. Patients may have received prior radiotherapy provided approval has been
             obtained by the Principal Investigator.

          -  Patients must be &lt; or = 75 years of age at the time of initial registration.

          -  Ejection fraction by ECHO or MUGA &gt;40% performed within 60 days prior to registration.

          -  Patients must have adequate pulmonary function studies &gt; or = 50% of predicted on
             mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) &gt; or =50% of
             predicted, within 60 days of registration. If the patient is unable to complete
             pulmonary function tests due to MM related pain or condition, there must be a
             pulmonary consult documenting that the patient is a candidate for high dose therapy.

          -  Patients must have a performance status of 0-2 based on SWOG criteria. Patients with a
             poor performance status (3-4), based solely on bone pain, will be eligible.

          -  All patients must be informed of the investigational nature of this study and must
             have signed an IRB-approved informed consent in accordance with institutional and
             federal guidelines.

        Induction Exclusion Criteria:

          -  Platelet count &lt; 30 x 10^9/L, unless myeloma-related

          -  ANC &lt; 1.0 X 10^9/L, unless myeloma-related

          -  Grade &gt; or =2 peripheral neuropathy

          -  Hypersensitivity to bortezomib, boron, or mannitol

          -  Uncontrolled diabetes.

          -  Recent (&lt; or =6 months) myocardial infarction, unstable angina, difficult to control
             congestive heart failure, uncontrolled hypertension, or difficult to control cardiac
             arrhythmias.

          -  Evidence of chronic obstructive or chronic restrictive pulmonary disease.

          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease free for at least three years.

          -  Patients must not have significant co-morbid medical conditions or uncontrolled life
             threatening infection.

          -  Pregnant or nursing women. Women of child-bearing potential must have a negative
             pregnancy test documented within one week of registration. Women and men of
             reproductive potential may not participate unless they have agreed to use an effective
             contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Barlogie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.myeloma.uams.edu</url>
    <description>Click here for more information about UAMS</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2004</study_first_submitted>
  <study_first_submitted_qc>April 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2004</study_first_posted>
  <results_first_submitted>September 18, 2015</results_first_submitted>
  <results_first_submitted_qc>September 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Treatment</title>
          <description>Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects &gt; 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Treatment</title>
          <description>Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects &gt; 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment</title>
        <description>In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a &gt;25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects &gt; 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment</title>
          <description>In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a &gt;25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Treatment</title>
          <description>Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects &gt; 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Anemia (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Anemia (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 CD4 count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Neutropenia/granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Neutropenia/granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombocytopenia (PLT)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombocytopenia (PLT)</sub_title>
                <counts group_id="E1" subjects_affected="296" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Coagulation-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhage, lower GI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hemorrhage, lower GI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhage, upper GI</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Edema-head and neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Edema-limb</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Edema-trunk/genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lymphatics-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 AV Block-Type 2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Asystole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Left vent. systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Left vent systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Supra Arrhythmia: atrial fib.</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Supra Arrhyth: Atrial Fib</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Supra Arrhyth: Atrial Flut</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Supra Arrhyth: Sinus Brady</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Vent arrhyth: Bigeminy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Ventricular Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Ventricular Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Ventricular Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Cardiac General</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Hearing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Cataract</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Flashing lights</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Necrosis gallblader</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Obstruction cecum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 GI Obstruction cecum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Perforation appendix</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Fatigue-lethargy, malaise, asthenia</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Fatigue-lethargy, malaise, asthenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Fatigue-malaise, lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Fever (in absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Fever (absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Anus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Bone</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Buttock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Cardiac/heart</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 External ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Extremity/limb</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Extremity/limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hip-left</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hip-right</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Joint</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lower back</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Lower back</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Middle back</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Neck</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Pleura</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Rib</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Stomach</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Throat pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Throat pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Upper back</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Upper back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Allergic reaction/Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Allergy-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Autoimmune reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Colitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Colitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Febrile neutropenia (ANC, fever)</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Febrile neutropenia (ANC, fever)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Infection 3-4 ANC abdomen</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Infection 3-4 ANC Appendix</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Infection 3-4 ANC Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GI Infection Unk ANC Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GU Infection 3-4 ANC Bladder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GU Infection Unk ANC UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection 3-4 ANC Blood</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Infection 3-4 ANC Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection 3-4 ANC Cath-related</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection 3-4 ANC Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection Unk ANC Cath-related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection Unk ANC for body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection (documented clinically or microbiologically)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC GI mild</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC Dermatology</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC General</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC Neurology</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/normal ANC Renal/Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection w/unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Infection w/unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection Clinical Doc. w/high ANC/Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection Normal ANC Lung (Bronchus)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection Normal Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection-Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung Infection-lung</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Lung infection-lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection-sinus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection-upper airway</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection Unk ANC-bronchus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection Unk ANC-lung</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Lung infection normal ANC-nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Opportunistic infection associated w/lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Opportunistic infection associated w/lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Opportunistic infection associated w/lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Viral hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Lung infection Unk ANC-bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Skin infection Unk ANC-skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GGT(Gamma-glutamyl transferase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Device/prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Gait/walking</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Gait/walking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle weakness-lower extrem.</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Muscle weakness-whole body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle weakness-whole body</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Musculoskeletal-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Soft tissue-abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Dizziness (includes lightneadedness, disequilibrium &amp; vertigo)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Dizziness (includes lightheadedness, disequilibrium &amp; vertigo)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Involuntary movement</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Mental status</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Mood alteration (agitation, anxiety, depression, euphoria)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Mood alteration (agitation, anxiety, depression, euphoria)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Mood/conscious change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Neurology-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Syncope</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Weakness-motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Bladder spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Bladder spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 GU fistula-bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Incontinence-urinary</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Renal-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Sexual-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 4 ARDS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 DLCO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 5 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Prolonged intubation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Pulmonary-other</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Dermatology-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Skin rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Skin rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Grade 3 HN Operative Injury-neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle operative Injury-joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Operative Injury-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombosis/embolism (vasc acc)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombosis/embolism (vasc acc)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hemorrhage-lower GI</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Edema-head and neck</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Edema-limb</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Edema-limb</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Lymphatics-other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Ventricular Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Ventricular Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Auditory/ear-other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hearing w/o monitoring program</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Colitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Constipation</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Constipation</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dysphagisa</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 GI-other</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Constitutional symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Fever (absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever (absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Sweating</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Sweating</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Bone</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Chest-thorax</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Head-headache</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Head-headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hip-left</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Joint</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Joint</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Lower back</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Lower back</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Middle back</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Middle back</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Muscle</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Neck</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Stomach</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Throat pharynx-larynx</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Upper back</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Upper back</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Opportunistic infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Infection (documented clinically or microbiologically)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Gait/walking</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Muscle weakness-whole body</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Muscle weakness-whole body</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Musculoskeletal-other</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Neurology-other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Sensory -neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Sensory-neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Incontinence-urinary</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Incontinence-urinary</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Renal-other</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Urinary frequency-urgency</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Urinary frequency-urgency</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Cough</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Cough</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Nasal/paranasal reactions</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Pulmonary-other</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Pulmonary-other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dermatology-other</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dermatology-other</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Flushing</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 1 Skin rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Grade 2 Skin rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials and Regulatory Affairs</name_or_title>
      <organization>The Myeloma Institute, University of Arkansas for Medical Sciences</organization>
      <phone>501-526-6990</phone>
      <email>npetty@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

